Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

FENNEC PHARMACEUTICALS INC.

FENC · Nasdaq · CIK 0001211583 · Healthcare · Biotechnology

INSIDER SIGNAL

No active buy signal

0 qualifying P purchase groups
in the current 180-day scoring window

55 Form 4 transaction lines observed in the same window
9 sales · 46 option, withholding, award, gift or other lines

Last qualifying purchase2025-05-19 · Hackman Jeffrey S. · $97.6K

WHY NO ACTIVE SIGNAL?

Purchase activityNone
Recent buyingNone
Recent salesModerate
Buy signal statusInactive
Score anatomy

No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.

ClusterNot calculated
Purchase sizeNot calculated
RoleNot calculated
RecencyNot calculated
ConvictionNot calculated

Why is there no score?

  • No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
  • Sales and other Form 4 activity remain visible as context and do not create a negative score.

Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
Raykov RostyOther
○○▼○○▼○○▼○▼○▼
Andrade RobertCHIEF FINANCIAL OFFICER
○○○○▼○○○○
Sayad Pierre SargisChief Medical Officer
○○○○○▼○○
Hackman Jeffrey S.Chief Executive Officer
○○○○○○○
Evans Terry LChief Commercial Officer
○○○○○○○
Cioffi Christiana MarieChief Strategy Officer
○○○○○○○
● Purchase▼ Sale○ Other

Showing the six most active owners; 2 additional owner(s) remain in Form 4 evidence.

Purchase breadth, concentration & cluster buying

These modules activate when qualifying purchases enter the 180-day research window.

SIGNAL HISTORY

No recorded active-signal snapshot

Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2025-05-19 · Hackman Jeffrey S..

Recent Form 4 activity

0Purchases
19Sales
68Other Form 4 lines
68SEC filings · 365 days
BUYING0 qualifying P line(s) · 180 days
SELLING9 sale line(s) · context only
OTHER46 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context has not been captured for this ticker yet. The daily market-context job processes the US universe in rotating batches.

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
513,287
Previous report
545,039
Avg daily volume
133,171
Days to cover
3.9

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2025-05-19Hackman Jeffrey S.Purchase (P)Common Shares13,965USD 6.99USD 97,615SEC filing ↗
2025-05-16Hackman Jeffrey S.Purchase (P)Common Shares1,035USD 6.75USD 6,986SEC filing ↗
2024-04-01Raykov RostyPurchase (P)Common shares29,167USD 0.00USD 0SEC filing ↗
2024-04-01Andrade RobertPurchase (P)Common shares12,500USD 0.00USD 0SEC filing ↗
2020-05-04Clark John Smith II; Southpoint Capital Advisors LLC; Southpoint Capital Advisors LP; Southpoint GP, LLC; Southpoint GP, LPPurchase (P)Common Stock80,000USD 6.25USD 500,000SEC filing ↗
2020-04-30CAVAZZA PAOLO; Cavazza Enrico; Cavazza Francesca; Cavazza Preta Martina; Cavazza Silvia; Essetifin SPAPurchase (P)Common Stock768,000USD 6.25USD 4,800,000SEC filing ↗

Form 4 evidence

87 transaction lines in the latest 365-day window; 264 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-10-12Sayad Pierre SargisAward / grant (A)Common Shares3,846USD 5.53USD 21,268SEC filing ↗
2026-10-12Hackman Jeffrey S.Award / grant (A)Common Shares2,224USD 5.53USD 12,299SEC filing ↗
2026-10-12Evans Terry LAward / grant (A)Common Shares2,326USD 5.53USD 12,863SEC filing ↗
Show recent Form 4 evidence (30 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-10-12Sayad Pierre SargisAward / grant (A)Common Shares3,846USD 5.53USD 21,268SEC filing ↗
2026-10-12Hackman Jeffrey S.Award / grant (A)Common Shares2,224USD 5.53USD 12,299SEC filing ↗
2026-10-12Evans Terry LAward / grant (A)Common Shares2,326USD 5.53USD 12,863SEC filing ↗
2026-10-12Cioffi Christiana MarieAward / grant (A)Common shares3,946USD 5.53USD 21,821SEC filing ↗
2026-10-12Andrade RobertAward / grant (A)Common shares3,846USD 5.53USD 21,268SEC filing ↗
2026-09-30Sayad Pierre SargisAward / grant (A)Common Shares168USD 0.00USD 0SEC filing ↗
2026-09-30Hackman Jeffrey S.Award / grant (A)Common Shares1,159USD 0.00USD 0SEC filing ↗
2026-09-30Evans Terry LAward / grant (A)Common Shares168USD 0.00USD 0SEC filing ↗
2026-09-30Cioffi Christiana MarieAward / grant (A)Common shares156USD 0.00USD 0SEC filing ↗
2026-09-30Andrade RobertAward / grant (A)Common shares1,703USD 0.00USD 0SEC filing ↗
2026-09-15Brughera Marco MariaSale (S)Common Shares15,545USD 10.29USD 159,958SEC filing ↗
2026-09-15Brughera Marco MariaOption exercise / conversion (M)Common Shares15,545USD 2.11USD 32,800SEC filing ↗
2026-09-01Raykov RostySale (S)Common shares10,000USD 12.11USD 121,100SEC filing ↗
2026-08-31Raykov RostyAward / grant (A)Common shares2,778USD 0.00USD 0SEC filing ↗
2026-08-31Sayad Pierre SargisSale (S)Common Shares12,000USD 12.18USD 146,160SEC filing ↗
2026-08-31Sayad Pierre SargisAward / grant (A)Common Shares168USD 0.00USD 0SEC filing ↗
2026-08-31Hackman Jeffrey S.Award / grant (A)Common Shares1,159USD 0.00USD 0SEC filing ↗
2026-08-31Evans Terry LAward / grant (A)Common Shares168USD 0.00USD 0SEC filing ↗
2026-08-31Cioffi Christiana MarieAward / grant (A)Common shares156USD 0.00USD 0SEC filing ↗
2026-08-31Andrade RobertAward / grant (A)Common shares1,703USD 0.00USD 0SEC filing ↗
2026-08-28Andrade RobertOption exercise / conversion (M)Common shares21,928USD 5.10USD 111,833SEC filing ↗
2026-08-27Andrade RobertSale (S)Common shares75,000USD 11.78USD 883,500SEC filing ↗
2026-08-03Raykov RostySale (S)Common shares10,000USD 9.58USD 95,800SEC filing ↗
2026-07-31Sayad Pierre SargisAward / grant (A)Common Shares168USD 0.00USD 0SEC filing ↗
2026-07-31Raykov RostyAward / grant (A)Common shares2,778USD 0.00USD 0SEC filing ↗
2026-07-31Hackman Jeffrey S.Award / grant (A)Common Shares1,159USD 0.00USD 0SEC filing ↗
2026-07-31Evans Terry LAward / grant (A)Common Shares168USD 0.00USD 0SEC filing ↗
2026-07-31Cioffi Christiana MarieAward / grant (A)Common shares156USD 0.00USD 0SEC filing ↗
2026-07-31Andrade RobertAward / grant (A)Common shares1,703USD 0.00USD 0SEC filing ↗
2026-07-01Raykov RostySale (S)Common shares9,599USD 10.41USD 99,926SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerFENC
CIK0001211583
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2836 Biological Products, (No Diagnostic Substances)
ExchangeNasdaq

Data coverage

Local Form 4 history264 transaction lines from 2020-04-30 to 2026-10-12
6 P purchase lines · 92 S sale lines · 166 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.